featured
Weekly Dose-Dense Chemotherapy as First-Line for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Lancet Oncol 2022 Jun 08;[EPub Ahead of Print], AR Clamp, EC James, IA McNeish, A Dean, JW Kim, DM O'Donnell, D Gallardo-Rincon, S Blagden, J Brenton, TJ Perren, S Sundar, R Lord, G Dark, M Hall, S Banerjee, RM Glasspool, CL Hanna, S Williams, KM Scatchard, H Nam, S Essapen, C Parkinson, L McAvan, AM Swart, B Popoola, F Schiavone, J Badrock, F Fananapazir, AD Cook, M Parmar, R Kaplan, JA LedermannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.